UCB announced today that the company has initiated a project
to build in-house biotech microbial manufacturing capacity in Bulle, Switzerland
to secure demand for its core product Cimzia® (certoluzimab pegol). The new
manufacturing unit should be operational in 2015 and requires an investment of
EUR 250 million in two steps.
“We want to be able to meet our projected future demand
for 2015 and beyond for Cimzia® – by adding internal capacity to our existing
capacities with our productions partners,” says Michele Antonelli,
Executive Vice President UCB and responsible for Technical Operations, Quality
Assurance and HSE. “Our site in Bulle is the right place and most cost
effective location to build our own biotech manufacturing unit which enables us
to further improve our productivity at attractive terms. The new unit together
with the bio-pilot-plant under construction in Braine l’Alleud, Belgium
will also strengthen our ability to deliver our future biological
products.”
